Compare Marqeta Inc (MQ) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Revvity Inc — how do they compare? Marqeta Inc trades at $15.94 (market cap $1.69B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Revvity Inc is far larger — about 8.4× Marqeta Inc's market cap, and Revvity Inc pays a 0.22% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | RVTY | |
|---|---|---|
Market Cap | $1.69B | $14.18B |
Sector | Technology | Technology |
52-Week High | $23.88 | $130.94 |
52-Week Low | $15.04 | $82.26 |
Enterprise Value | $1.01B | $16.50B |
Dividend Yield | — | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $16.26, down 1.93% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive net cash flow of $86.42M in 2025. Recent developments include expansion of Google Wallet partnership and stablecoin card initiatives. Valuation metrics remain elevated with P/E of 180.89 and EV/EBITDA of 48.53 despite modest profitability margins.
MQ offers 26% upside to consensus price target of $19.00, supported by earnings estimate revisions and strategic partnerships. Key risks include high valuation multiples, competitive payment processing landscape, and the need to sustain recent profitability improvements. Institutional sentiment leans cautious with 59% hold ratings despite recent business momentum.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
